<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="are no certain data yet. However, research on asymptomatic viral" exact="infection" post="is currently ongoing worldwide to elucidate the real prevalence"/>
 <result pre="viral infection is currently ongoing worldwide to elucidate the real" exact="prevalence" post="and mortality of the disease. From a clinical point"/>
 <result pre="tissues and organs through the Spike (S) protein. Currently, SARS-CoV-2" exact="infection" post="is prevented by the use of masks, social distancing,"/>
 <result pre="Currently, SARS-CoV-2 infection is prevented by the use of masks," exact="social distancing," post="and improved hand hygiene measures. This review summarizes the"/>
 <result pre="touching contaminated surfaces. No other route of transmission of coronavirus" exact="infection" post="has been documented thus far. The virus replicates locally"/>
 <result pre="The predominant illness associated with CoVs is an upper respiratory" exact="infection" post="with occasional cases of pneumonia in infants and young"/>
 <result pre="bats [7]. The common cold is due to a viral" exact="infection" post="of the upper respiratory tract. A total of more"/>
 <result pre="often more than one viral species is involved in the" exact="infection" post="at the same time. The most commonly responsible virus"/>
 <result pre="a secondary host and reservoir for the continuation of the" exact="infection" post="and then the SARS emergency [21]. The SARS epidemic,"/>
 <result pre="enzyme in the Renin-Angiotensin system and a target for the" exact="treatment" post="of hypertension [22]. The Spike/ACE2 interaction triggers a violent"/>
 <result pre="activated leukocytes [28]. The MERS has never disappeared and the" exact="infection" post="continues to be transmitted to humans by camelids, matt,"/>
 <result pre="2019 [32]. In Italy, the first cases of CoV 2019-nCoV" exact="infection" post="were diagnosed at the end of January in a"/>
 <result pre="is even 97.25% (Table 2). Currently, the main source of" exact="infection" post="is the patient with SARS-CoV-2. Patients with non-clinically evident"/>
 <result pre="[11,51]. Recently, the fecal specimen was highly recommended for routine" exact="detection" post="of SARS-CoV-2 and especially before discharging COVID-19 patients [52]."/>
 <result pre="were negative for RT-PCR for SARS-CoV-2 [55]. However, the neonatal" exact="diagnosis" post="of SARS-CoV-2 should not be limited to molecular testing,"/>
 <result pre="method, without any clinical suspicion and/or risk factor for SARS-CoV-2" exact="infection" post="[56]. More detailed studies will be required to confirm"/>
 <result pre="CoV, like SARS, uses ACE2 receptor, a target for the" exact="treatment" post="of hypertension [22], to gain entry to cells. Accumulating"/>
 <result pre="SARS-CoV-2 [59]. A TMPRSS2 inhibitor blocking entry might constitute a" exact="treatment" post="option of SARS-CoV-2 [60]. Thus, SARS-CoV-2 cell entry depends"/>
 <result pre="genetic and hormonal factors, to give more protection to COVID-19" exact="infection" post="and make them less susceptible [62]. Studies are underway"/>
 <result pre="site for SARS-CoV-2. However, less than 10% of children with" exact="infection" post="develop diarrhea and vomiting [65]. The infection of human"/>
 <result pre="of children with infection develop diarrhea and vomiting [65]. The" exact="infection" post="of human gut epithelium has important implications for fecalâ€&quot;oral"/>
 <result pre="of lung inflammatory cell infiltration, is the key to improving" exact="treatment" post="success rates and reducing mortality rates in patients with"/>
 <result pre="tissues involved by SARS-CoV-2 [70]. The initial stages of COVID-19" exact="infection" post="are nonspecific and include symptoms typical of multiple respiratory"/>
 <result pre="far, 80.9% of patients infected with the virus develop mild" exact="infection" post="and include symptoms nonspecific and typical of multiple respiratory"/>
 <result pre="occur simultaneously with COVID-19, should be considered in the differential" exact="diagnosis" post="(Table 1). In agreement with Chinese studies, patients develop"/>
 <result pre="suggesting fever is dominant, but not the main symptom of" exact="infection" post="(Figure 2). A small number of patients can have"/>
 <result pre="compromise their immune systems, may increase the risk of SARS-CoV-2" exact="infection" post="[48]. Smoking may be a negative prognostic indicator for"/>
 <result pre="cases, in children the immune response is more balanced towards" exact="infection" post="and there is often an optimal recovery within a"/>
 <result pre="Guillain-Barre syndrome have been reported to be associated with SARS-CoV-2" exact="infection" post="[44,79]. The neuroinvasive propensity of SARS-CoV-2 has, therefore, already"/>
 <result pre="and elevated procalcitonin [31,48,70,77]. 8. Diagnosis of SARS-CoV-2 Infection SARS-Cov-2" exact="infection" post="diagnosis is mostly performed by the reverse transcription polymerase"/>
 <result pre="elevated procalcitonin [31,48,70,77]. 8. Diagnosis of SARS-CoV-2 Infection SARS-Cov-2 infection" exact="diagnosis" post="is mostly performed by the reverse transcription polymerase chain"/>
 <result pre="SARS-CoV-2 Infection SARS-Cov-2 infection diagnosis is mostly performed by the" exact="reverse transcription polymerase chain reaction" post="(RT-PCR) assay for viral RNA detection, according to the"/>
 <result pre="SARS-Cov-2 infection diagnosis is mostly performed by the reverse transcription" exact="polymerase chain reaction" post="(RT-PCR) assay for viral RNA detection, according to the"/>
 <result pre="alternative with 95% positive and 100% negative predictive agreement, point-of-care" exact="testing" post="using Specific High Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) diagnostics"/>
 <result pre="information on the evolution of the epidemic. In this regard," exact="testing" post="of specimens from multiple sites may improve the sensitivity"/>
 <result pre="SARS-CoV-2, the serum immunoglobulin (Ig) anti-SARS-CoV-2 type M (IgM)/IgG antibody" exact="detection" post="against the SARS-CoV-2 internal nucleoprotein (NP) and surface spike"/>
 <result pre="surface spike protein receptor-binding domain (RBD) may be used in" exact="diagnosis" post="of COVID-19 and to monitor the disease stages and"/>
 <result pre="COVID-19 and to monitor the disease stages and identify past" exact="infection" post="and immunity [83,86]. So far, it remains to be"/>
 <result pre="to be determined the value of serological assays for the" exact="detection" post="of human immunoglobulin (Ig) anti-SARS-CoV-2 type M (IgM) or"/>
 <result pre="anti-SARS-CoV-2 type M (IgM) or type G (IgG) in the" exact="diagnosis" post="and monitoring of COVID-19, especially for patients with acute"/>
 <result pre="NPS/OPS were carried out on symptomatic subjects only. When the" exact="infection" post="spread to other Italian regions including Veneto, it became"/>
 <result pre="symptoms. Veneto was the region that first pursued early SARS-CoV-2" exact="detection" post="by searching for the virus even in asymptomatic subjects"/>
 <result pre="testosterone seems to favor a more severe evolution of the" exact="infection" post="in some cases. In this context, females seem to"/>
 <result pre="genetic and hormonal factors, to give more protection to SARS-CoV-2" exact="infection" post="and make them less susceptible [62]. Studies are underway"/>
 <result pre="support these hypotheses. 4. So far, serological assays for the" exact="detection" post="of human IgM and IgG currently have limitations in"/>
 <result pre="completely reliable immunological assays have yet been developed for the" exact="detection" post="of serum antibodies against SARS-CoV-2. They probably will be"/>
 <result pre="allowed to isolate those individuals resulted positive for SARS-CoV-2 and" exact="quarantine" post="them, thus avoiding and blocking the spread of the"/>
 <result pre="the proportion is closer to 5% [90,91]. Research of asymptomatic" exact="infection" post="among swab positive persons is currently ongoing worldwide to"/>
 <result pre="positive persons is currently ongoing worldwide to elucidate the real" exact="prevalence" post="of the disease and the true relative mortality ratio."/>
 <result pre="symptomatic versus asymptomatic infections, highlighting the importance of asymptomatic SARS-CoV-2" exact="infection" post="[92]. Moreover, asymptomatic individuals have shown a weaker immune"/>
 <result pre="during the early convalescent phase. Therefore, timely RTâ€&quot;PCR and serological" exact="testing" post="should be used in conjunction, which would benefit accurate"/>
 <result pre="distributed to patients. The search for effective treatments for COVID-19" exact="infection" post="is a complex process and not all are recommended"/>
 <result pre="substance in SARS-CoV-1 or MERS-CoV that could be repositioned for" exact="treatment" post="of SARS-CoV-2 infections. RNA-Dependent RNA Polymerase Inhibitors (RdRp). Among"/>
 <result pre="and Drug Administration (FDA), to employ in emergency for the" exact="treatment" post="of COVID-19 in adults and children hospitalized with severe"/>
 <result pre="of action of RDV makes it potentially useful in the" exact="treatment" post="of COVID-19. At least 23 studies of RDV are"/>
 <result pre="RNA replication [90]. Favipiravir is a guanine analog approved for" exact="treatment" post="against influenza virus infection in Japan and also can"/>
 <result pre="is a guanine analog approved for treatment against influenza virus" exact="infection" post="in Japan and also can effectively inhibit replication of"/>
 <result pre="SARS-CoV-2 viruses, has been identified as a promising target for" exact="treatment" post="of COVID-19 [59]. The TMPRSS2 cell entry of SARS-CoV-2"/>
 <result pre="to be a very promising and specific approach for the" exact="treatment" post="of SARS-COV-2 infection [104]. This could represent a promising"/>
 <result pre="very promising and specific approach for the treatment of SARS-COV-2" exact="infection" post="[104]. This could represent a promising specific approach in"/>
 <result pre="[104]. This could represent a promising specific approach in the" exact="treatment" post="of COVID-19 also on the basis of experience gained"/>
 <result pre="emerged as one of the most intense and overwhelming viral" exact="infection" post="for the humankind to manage. As the number of"/>
 <result pre="RDV), antiparasitic (i.e., hydroxychloroquine), and anti-inflammatory approaches (i.e., tocilizumab) for" exact="treatment" post="of COVID-19. In the light of the exuberance of"/>
 <result pre="and Mycoplasma human infectionsFuture Microbiol.2007237337610.2217/17460913.2.4.37317683273 11.ZhangN.WangL.DengX.LiangR.SuM.HeC.HuL.SuY.RenJ.YuF.et al.Recent advances in the" exact="detection" post="of respiratory virus infection in humansJ. Med. Virol.20209240841710.1002/jmv.2567431944312 12.collab:"/>
 <result pre="Microbiol.2007237337610.2217/17460913.2.4.37317683273 11.ZhangN.WangL.DengX.LiangR.SuM.HeC.HuL.SuY.RenJ.YuF.et al.Recent advances in the detection of respiratory virus" exact="infection" post="in humansJ. Med. Virol.20209240841710.1002/jmv.2567431944312 12.collab: World Health OrganizationConsensus Document"/>
 <result pre="Europe: A case seriesLancet Infect. Dis.20202069770610.1016/S1473-3099(20)30200-032224310 41.HoehlS.RabenauH.BergerA.KortenbuschM.CinatlJ.BojkovaD.BehrensP.BÃ¶ddinghausB.GÃ¶tschU.NaujoksF.et al.Evidence of SARS-CoV-2" exact="infection" post="in returning travelers from Wuhan, ChinaN. Engl. J. Med.20203821278128010.1056/NEJMc200189932069388"/>
 <result pre="from Wuhan, ChinaN. Engl. J. Med.20203821278128010.1056/NEJMc200189932069388 42.RotheC.SchunkM.SothmannP.Gisela BretzelG.FroeschlG.WallrauchC.ZimmerT.ThielV.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.202038297097110.1056/NEJMc200146832003551"/>
 <result pre="clinical specimensJAMA20203231843184410.1001/jama.2020.3786 52.MimM.A.Naznin RakhiN.SahaO.RahamanM.M.Recommendation of fecal specimen for routine molecular" exact="detection" post="of SARS-CoV-2 and for COVID-19 discharge criteriaPathog. Glob. Health202011416816932407189"/>
 <result pre="coronavirus infections and pregnancy outcomesArch. Pathol. Lab. Med.202010.5858/arpa.2020-0901-SA 56.CalderaroA.ArcangelettimM.C.De ContoF.ButtriniM.MontagnaP.MontecchiniS.FerragliaF.PinardiF.ChezziC.SARS-CoV-2" exact="infection" post="diagnosed only by cell culture isolation before the local"/>
 <result pre="Lab. Med.202010.5858/arpa.2020-0901-SA 56.CalderaroA.ArcangelettimM.C.De ContoF.ButtriniM.MontagnaP.MontecchiniS.FerragliaF.PinardiF.ChezziC.SARS-CoV-2 infection diagnosed only by cell culture" exact="isolation" post="before the local outbreak in an Italian seven-week-old suckling"/>
 <result pre="with acute respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 67.YeQ.WangB.MaoJ.The pathogenesis and" exact="treatment" post="of the â€˜Cytokine Stormâ€™ in COVID-19J. Infect.20208060761310.1016/j.jinf.2020.03.03732283152 68.RuscittiP.BerardicurtiO.IagnoccoA.GiacomelliR.Cytokine storm"/>
 <result pre="and COVID-19Rev. Neurol.20207031132232329044 80.ClerkinK.J.FriedJ.A.RaikhelkarJ.SayerG.GriffinJ.M.MasoumiA.JainS.S.BurkhoffD.KumaraiahD.RabbaniL.et al.COVID-19 and Cardiovascular DiseaseCirculation20201411648165510.1161/CIRCULATIONAHA.120.04694132200663 81.BroughtonJ.P.DengX.YuG.FaschingC.L.ServellitaV.SinghY.MiaoX.StreithorstY.A.GranadosA.Sotomayor-GonzalezA.et al.CRISPR-Cas12-based" exact="detection" post="of SARS-CoV-2Nat. Biotechnol.20203887087410.1038/s41587-020-0513-432300245 82.JoungJ.LadhaA.SaitoM.SegelM.BruneauR.HuangM.W.KimN.G.YuX.LiJ.WalkerB.D.et al.Point-of-care testing for COVID-19 using"/>
 <result pre="Cardiovascular DiseaseCirculation20201411648165510.1161/CIRCULATIONAHA.120.04694132200663 81.BroughtonJ.P.DengX.YuG.FaschingC.L.ServellitaV.SinghY.MiaoX.StreithorstY.A.GranadosA.Sotomayor-GonzalezA.et al.CRISPR-Cas12-based detection of SARS-CoV-2Nat. Biotechnol.20203887087410.1038/s41587-020-0513-432300245 82.JoungJ.LadhaA.SaitoM.SegelM.BruneauR.HuangM.W.KimN.G.YuX.LiJ.WalkerB.D.et al.Point-of-care" exact="testing" post="for COVID-19 using SHERLOCK diagnosticsmedRxiv202010.1101/2020.05.04.20091231 83.CarterL.J.GarnerL.V.SmootJ.W.LiY.ZhouQ.SavesonC.J.SassoJ.M.GreggA.C.SoaresD.J.BeskidT.R.et al.Assay Techniques and"/>
 <result pre="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance(accessed on 3 March 2020) 86.WangH.LiX.LiT.ZhangS.WangL.WuX.LiuJ.The genetic sequence, origin, and" exact="diagnosis" post="of SARS-CoV-2Eur. J. Clin. Microbiol. Infect. Dis.20201710.1007/s10096-020-03899-431811506 87.StowellS.GuarnerJ.Role of"/>
 <result pre="Xue Za Zhi2020411632062933 91.JinY.CaiL.ChengZ.ChengH.DengT.FanY.P.FangC.HuangD.HuangL.Q.HuangQ.et al.A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
 <result pre="Zhi2020411632062933 91.JinY.CaiL.ChengZ.ChengH.DengT.FanY.P.FangC.HuangD.HuangL.Q.HuangQ.et al.A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil."/>
 <result pre="anti-inflammatory treatmentsLancet Infect. Dis.20202040040210.1016/S1473-3099(20)30132-832113509 102.ZhangS.LiL.ShenA.ChenY.QiZ.Rational use of Tocilizumab in the" exact="treatment" post="of novel coronavirus pneumoniaClin. Drug Investig.20204051151810.1007/s40261-020-00917-3 103.WangH.YangP.LiuK.GuoF.ZhangY.ZhangG.JiangC.SARS coronavirus entry"/>
 <result pre="Â°Â° Mycoplasma pneumoniae Â°Â° Chlamydia pneumoniae Â°Â° * Human metapneumovirus" exact="infection" post="include pneumonia, otitis media, bronchiolitis, exacerbations of asthma, or"/>
</results>
